ClinicalTrials.gg

Program

KN057

A development code. Also written as “KN057 doseⅠ”, “KN057 dose Ⅱ” and “KN057 dose Ⅲ”.

Its studies are mostly in Hemophilia A, led by Suzhou Alphamab.

Furthest: phase 3, since Dec 30, 20235 company-led studies, 4 open or runningNext primary completion: Dec 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Alphamab54 open or runningphase 3since Dec 30, 2023Jun 9, 2022Dec 30, 2027phase 3 · NCT07545395

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2022First study: phase 2 study in Hemophilia AFirst studyNCT05421429 · 24 enrolled · China
  2. Dec 30, 20232 phase 3 studiesNCT06569108, NCT06312475
  3. Dec 11, 2024Phase 2 study in Hemophilia ANCT06747416 · 24 planned
  4. Mar 8, 2026Phase 3 study in Hemophilia ANCT07545395 · 70 planned · China

Ahead

  1. Dec 30, 2027Primary completion: phase 3 study in Hemophilia ANCT07545395

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07545395Hemophilia A · China3RecruitingDec 30, 202770
NCT06747416Hemophilia A2Not yet recruitingSep 2, 202624
NCT06569108Hemophilia A Without Inhibitor · China3Active, not recruitingOct 15, 2026125
NCT06312475Hemophilia A With Inhibitor · China3Active, not recruitingOct 15, 202553
NCT05421429Hemophilia A · China2CompletedJan 17, 202424

How it is read

Names in the registry

  • “KN057”, 4 entries
  • “KN057 doseⅠ”, 1 entry
  • “KN057 dose Ⅱ”, 1 entry
  • “KN057 dose Ⅲ”, 1 entry

Codes read as this program: KN057.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.